Reeling from past failures, Parkinson’s pipeline enters ‘era of diversification’

While some drugmakers continue to walk the alpha-synuclein antibody path, others like AC Immune opt for new approaches that could bring the first-ever disease-modifying therapy for Parkinson’s disease.